4SC AG announced that the first clinical centers of the investigator-sponsored Phase II study EMERGE are open for patient recruitment. The study is conducted by Prof. David Cunningham, Head of the Gastrointestinal and Lymphoma Unit and Director of Clinical Research at The Royal Marsden NHS Foundation Trust. The multi-center, single-arm, open-label study examines domatinostat plus checkpoint inhibitor avelumab in up to 70 patients with advanced gastrointestinal cancer - precisely microsatellite-stable esophago-gastric and colorectal cancer. The study is intended to establish the safety of combining domatinostat with avelumab as well as to generate proof-of-concept clinical data in this patient population.